title: [Improvement of left ventricular hypertrophy by anemic-correcting erythropoietin therapy in chronic renal insufficiency].
abstract: OBJECTIVE
  Left ventricular hypertrophy (LVH) is an independent predictor of morbidity and mortality in dialysis patients. It remains unclear whether efforts to correct anemia in patients with mild-to-moderate chronic renal insufficiency (CRI) can reverse LVH. This prospective multi-center Chinese cohort study evaluates left ventricular mass index (LVMI) evolution in anemic CRI patients with or without recombinant human erythropoietin (rHuEPO) therapy.
  
  
  METHODS
  Six centers enrolled 158 patients with serum creatinine from 147 to 400 micromol/L, and 86 of whom with hemoglobin (Hb) levels < 110 g/L received rHuEPO (Group A). Forty patients with comparable Hb levels (< 110 g/L) but did not receive rHuEPO (Group B) and those with Hb >/= 110 g/L (Group C, n = 32) were served as controls. Echocardiographic studies were performed to evaluate LVMI at baseline and every 3 months during a two-year period.
  
  
  RESULTS
  At baseline, the prevalence of LVH was 72.1% in Group A, 72.5% in Group B and 59.4% in Group C. LVMI was inversely correlated with Hb levels (r = -0.70, P < 0.01). There was no difference in age, gender, aetiology of renal failure, blood pressure (BP) and cardiovascular risk factors between the 3 groups. The administration of rHuEPO in Group A significantly increased Hb levels from (93.8 +/- 14.6) g/L to (111.2 +/- 10.3) g/L and decreased LVMI from (142.6 +/- 25.7) g/m(2) to (132.4 +/- 18.5) g/m(2). The prevalence of LVH decreased 16.3% after a partial correction of anemia at 24 months, whereas Hb levels in controls (Group B and Group C) tended to decrease and LVMI significantly increased compared with baseline. The prevalence of LVH was significantly increased in Group B and C after 24 months. The percentage of patients whose serum creatinine level doubled during the follow-up was 3.4% in Group A, 15.0% in Group B and 9.4% in Group C, the difference between Group A and Group B being significant (P < 0.05). In addition, good BP control was obtained without any adverse effects.
  
  
  CONCLUSIONS
  High prevalence of LVH was present in pre-dialysis CRI patients, which is associated with severity of anemia. Early treatment of anemia with rHuEPO can reverse LVH in CRI patients.
authors.affiliation: Division of Nephrology, Nanfang Hospital, Guangzhou 510515, China.
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Jiang
authors.forename: Fan-Fan
authors.initials: FF
authors.lastname: Hou
authors.forename: Li-Zhen
authors.initials: LZ
authors.lastname: Gao
authors.forename: Yang-Bin
authors.initials: YB
authors.lastname: Pan
authors.forename: Nian-Sheng
authors.initials: NS
authors.lastname: Yang
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Gui-Yang
authors.initials: GY
authors.lastname: Shu
authors.forename: You-Ming
authors.initials: YM
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
authors.forename: Wei-Hua
authors.initials: WH
authors.lastname: Peng
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Wu
authors.forename: Zhong-Min
authors.initials: ZM
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000150:complications / Q000188:drug therapy*; D015331:Cohort Studies; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin